| Sign In to gain access to subscriptions and/or personal tools. |
Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three casesMedical Faculty, Psychiatry Department, Uludag University, Bursa, Turkey cakkaya{at}uludag.edu.tr
Medical Faculty, Psychiatry Department, Uludag University, Bursa, Turkey
Medical Faculty, Psychiatry Department, Uludag University, Bursa, Turkey
Medical Faculty, Psychiatry Department, Uludag University, Bursa, Turkey
Medical Faculty, Endocrinology Department, Uludag University, Bursa, Turkey
Medical Faculty, Psychiatry Department, Uludag University, Bursa, Turkey Abstract Schizophrenia is a chronic and debilitating psychotic mental disorder that affects about 1% of the world's population. Antipsychotic drugs are the mainstay of treatment in schizophrenia. Hyperprolactinemia, which is a common side effect of typical antipsychotics, is also associated with the use of some of the newer atypical agents. Antipsychotics may enhance prolactinoma growth as manifested by an increase in serum prolactin concentration. Prolactin-secreting pituitary adenomas possibly related with antipsychotics have been described in the literature. To our knowledge, this is the first series of cases showing a possible relation between pituitary adenomas and amisulpride treatment in patients with schizophrenia.
Key Words: amisulpride hyperprolactinemia pituitary adenoma
This version was published on August
1, 2009 Journal of Psychopharmacology, Vol. 23, No. 6,
723-726 (2009) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||